EM2 Pill - pink round, 7mm
Pill with imprint EM2 is Pink, Round and has been identified as Oxybutynin Chloride Extended-Release 10 mg. It is supplied by Accord Healthcare, Inc.
Oxybutynin is used in the treatment of Overactive Bladder; Neurogenic Detrusor Overactivity; Dysuria; Urinary Incontinence; Urinary Frequency and belongs to the drug class urinary antispasmodics. There is no proven risk in humans during pregnancy. Oxybutynin 10 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for EM2
Oxybutynin Chloride Extended-Release
- Imprint
- EM2
- Strength
- 10 mg
- Color
- Pink
- Size
- 7.00 mm
- Shape
- Round
- Availability
- Rx and/or OTC
- Drug Class
- Urinary antispasmodics
- Pregnancy Category
- B - No proven risk in humans
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Accord Healthcare, Inc.
- National Drug Code (NDC)
- 16729-0318
- Inactive Ingredients
-
polyethylene glycol,
sodium bicarbonate,
sodium lauryl sulfate,
magnesium silicate,
titanium dioxide,
triethyl citrate,
ferric oxide yellow,
ferric oxide red,
silicon dioxide,
hypromelloses,
lactose monohydrate,
magnesium stearate,
methacrylic acid - ethyl acrylate copolymer (1:1) type a,
microcrystalline cellulose
Note: Inactive ingredients may vary.
Related images for "EM2"
More about oxybutynin
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (450)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: urinary antispasmodics
Patient resources
- Oxybutynin drug information
- Oxybutynin transdermal
- Oxybutynin (Oral) (Advanced Reading)
- Oxybutynin (Transdermal) (Advanced Reading)
- Oxybutynin Extended-Release Tablets
Other brands
Ditropan, Ditropan XL, Oxytrol, Gelnique, Anturol
Professional resources
Other brands
Ditropan, Ditropan XL, Oxytrol, Gelnique
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
